Medxy AI – Page 162

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

By MedXY 09/08/2025

Patritumab deruxtecan (HER3-DXd) demonstrates notable efficacy and manageable safety in heavily pretreated advanced NSCLC, including patients without EGFR mutations, offering a potential new treatment avenue.

Clinical Updates news Oncology Specialties

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

By MedXY 09/08/2025

This phase II study demonstrates that the combination of avutometinib and defactinib offers significant clinical benefit with manageable safety in recurrent low-grade serous ovarian cancer, particularly in KRAS-mutant tumors.

Clinical Updates Oncology Specialties

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

By MedXY 09/08/2025

The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting safety concerns that preclude further development.

Clinical Updates news Oncology Specialties

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

By MedXY 09/08/2025

The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cell carcinoma of the head and neck.

Clinical Updates news Oncology Pathology & Lab Medicine

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

By MedXY 09/08/2025

A new cell-free DNA fragmentomics model combined with machine learning achieves high accuracy for early pancreatic cancer detection, potentially improving patient outcomes through timely intervention.

Clinical Updates Oncology

Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC: Advancing Preoperative Therapeutics

By MedXY 09/08/2025

Neoadjuvant osimertinib, alone or with chemotherapy, significantly improves major pathological response rates in resectable EGFR-mutated NSCLC, offering a promising approach to enhance surgical outcomes and event-free survival with an acceptable safety profile.

AI Clinical Updates Specialties

AI Revolutionizing Pharma: From Drug Discovery to Clinical Application Through Intelligent Innovation

By MedXY 09/08/2025

Artificial intelligence is dramatically transforming pharmaceutical R&D by accelerating drug discovery, formulation, and clinical trials, while presenting new opportunities and challenges for the industry, especially in China.

Clinical Updates news Oncology Specialties

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials

By MedXY 09/08/2025

Venous and arterial thrombotic events in cancer patients are underreported in clinical trials, impairing risk assessment and prevention strategies. Uniform and comprehensive reporting is imperative to improve patient outcomes and guide therapeutic decisions.

Clinical Updates Family Medicine & Nutrition news

Rapamycin and Aging: Insights from the PEARL Trial on Safety and Healthspan Enhancements After One Year

By MedXY 09/08/2025

The PEARL trial demonstrates that low-dose, intermittent rapamycin is safe in healthy aging adults and improves lean tissue mass and pain in women, with additional benefits in emotional well-being and general health at lower doses.

Family Medicine & Nutrition news Urology

The Silent Decline: Understanding the Post-Pandemic Drop in Sexual Activity Among Americans

By MedXY 09/08/2025

A recent study highlights a historic decline in sexual activity in the U.S., driven by societal, psychological, and lifestyle factors, affecting all ages and calling for renewed attention to sexual health.

Clinical Updates Diabetes & Endocrinology news Oncology

Type 2 Diabetes and Colorectal Cancer: Immune Landscape Shapes Risk and Survival Outcomes

By MedXY 09/08/2025

Type 2 diabetes increases colorectal cancer risk and worsens survival, particularly in tumors with low immune cell infiltration, highlighting the interplay between metabolic and immune factors in cancer progression and prognosis.

Clinical Updates news OB/GYN & Women's Health Oncology

EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation

By MedXY 09/08/2025

The phase III EPIK-O trial showed no progression-free survival benefit of alpelisib plus olaparib over chemotherapy in BRCA wild-type platinum-resistant or refractory high-grade serous ovarian cancer, highlighting treatment challenges and biomarker insights.

Clinical Updates news Oncology

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

By MedXY 09/08/2025

Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemotherapy.

Cardiology

Kidney Tubular Biomarkers as Predictors of Mortality and Heart Failure Readmission in Acute Heart Failure Patients

By MedXY 09/08/2025

Kidney tubular damage biomarkers independently predict death and heart failure readmission in acute heart failure, highlighting novel risk stratification beyond traditional glomerular measures.

Clinical Updates Family Medicine & Nutrition news

Timing Matters: Determining the Optimal Duration of Supervised Exercise for Meaningful Improvements in Peripheral Artery Disease

By MedXY 09/08/2025

A supervised treadmill exercise program lasting over 6 weeks is essential to achieve significant walking improvements in peripheral artery disease, with peak patient-reported benefits observed at 12 weeks but diminishing by 26 weeks.

Cardiology news Pathology & Lab Medicine

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

By MedXY 09/08/2025

Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.

Family Medicine & Nutrition news Oncology

10 Habits That Cancer Cells Fear: Building Your Body’s Natural Defense

By MedXY 09/08/2025

Explore ten evidence-based lifestyle habits that significantly reduce cancer risk and empower your body’s natural defenses against cancer development.

Diabetes & Endocrinology news

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial

By MedXY 09/08/2025

The OASIS 2 trial shows oral semaglutide 50 mg significantly reduces body weight in East Asian adults with overweight or obesity, with or without type 2 diabetes, offering a promising therapeutic option with manageable safety profile.

Diabetes & Endocrinology Specialties

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

By MedXY 09/07/2025

A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerability.

Diabetes & Endocrinology Specialties

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

By MedXY 09/07/2025

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC: Advancing Preoperative Therapeutics

AI Revolutionizing Pharma: From Drug Discovery to Clinical Application Through Intelligent Innovation

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials

Rapamycin and Aging: Insights from the PEARL Trial on Safety and Healthspan Enhancements After One Year

The Silent Decline: Understanding the Post-Pandemic Drop in Sexual Activity Among Americans

Type 2 Diabetes and Colorectal Cancer: Immune Landscape Shapes Risk and Survival Outcomes

EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

Kidney Tubular Biomarkers as Predictors of Mortality and Heart Failure Readmission in Acute Heart Failure Patients

Timing Matters: Determining the Optimal Duration of Supervised Exercise for Meaningful Improvements in Peripheral Artery Disease

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

10 Habits That Cancer Cells Fear: Building Your Body’s Natural Defense

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

The Hidden Driver of Chronic Pain: How Macrophages Fuel Neuropathic Symptoms

Basal Ganglia Perivascular Spaces: A Dual-Risk Biomarker for Ischemic Stroke and Major Bleeding in Antithrombotic Therapy

Selective D1/D5 Receptor Agonism in Parkinson Disease: Insights from the TEMPO-3 Phase 3 Trial of Tavapadon

Long-Term Health Risks Following Postoperative Hypoparathyroidism in Thyroid Cancer Patients